IPO

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

A new AI tool clarifies accented English for listeners in real time, sparking both excitement for global business and debate over cultural identity.

As Uni-Fuels blankets Thailand with bunkering services, the move highlights the nation's rising maritime importance and the intense battle for market share.

A new partnership uses AI and real-time payments to slash financial risk, unlock capital, and turn energy-hungry industries into powerful grid allies.

With a new focus and fresh capital, Trigon Metals begins a key drilling campaign at its Addana project, betting on Moroccan silver to power the future.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

Riot Platforms reports a record $647M revenue for 2025, but a staggering net loss and a strategic pivot to data centers raises critical questions.

Entrepreneur Daniel Gestetner discusses resilience, a $1B exit, and why true success isn't about winning at all costs in a revealing new podcast.

Cuentas and Hallo 015 launch a unique MVNO service, blending mobile connectivity and exclusive content for the growing Israeli community in the United States.

With a new unified command under mining veteran Mark Wall, American Rare Earths aims to accelerate its massive Halleck Creek project and secure the U.S. supply chain.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

Amid intense market volatility, firms are turning to AI-powered energy storage to protect profits. One company's $53M deal shows how it's done.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

As Middle East conflict roiled markets, 24/7 on-chain gold offered an immediate safe haven, challenging the dominance of traditional financial systems.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.